Charles Schwab Investment Management Inc Biotechnology

Charles Schwab Investment Management Inc

$521 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
CDXC Chroma Dex Corp.	$420M	$997,000 0.0% of portfolio	144,623	Q1 2025 Added 0.0%
DSGN Design Therapeutics, Inc.	$225M	$997,000 0.0% of portfolio	258,375	Q1 2025 Reduced 2.38%
NKTR Nektar Therapeutics	$4.61B	$975,000 0.0% of portfolio	1,434,457	Q1 2025 Reduced 2.16%
FDMT 4 D Molecular Therapeutics, Inc.	$149M	$913,000 0.0% of portfolio	282,781	Q1 2025 Reduced 8.37%
ENTA Enanta Pharmaceuticals Inc	$152M	$882,000 0.0% of portfolio	159,801	Q1 2025 Added 3.21%
LYEL Lyell Immunopharma, Inc.	$2.58B	$866,000 0.0% of portfolio	1,604,676	Q1 2025 Reduced 2.5%
AURA Aura Biosciences, Inc.	$207M	$811,000 0.0% of portfolio	138,466	Q4 2024 Added 0.08%
EDIT Editas Medicine, Inc.	$224M	$794,000 0.0% of portfolio	684,896	Q1 2025 Added 12.6%
ALDX Aldeyra Therapeutics, Inc.	$317M	$793,000 0.0% of portfolio	137,985	Q1 2025 Added 0.92%
VRCA Verrica Pharmaceuticals Inc.	$327M	$791,000 0.0% of portfolio	99,505	Q1 2025 Added 127.95%
MGTX Meira G Tx Holdings PLC	$374M	$786,000 0.0% of portfolio	116,027	Q1 2025 Added 3.58%
ZNTL Zentalis Pharmaceuticals, Inc.	$83.8M	$773,000 0.0% of portfolio	486,499	Q1 2025 Reduced 2.18%
CHRS Coherus Bio Sciences, Inc.	$79.3M	$770,000 0.0% of portfolio	950,676	Q1 2025 Reduced 2.68%
ALEC Alector, Inc.	$148M	$768,000 0.0% of portfolio	624,730	Q1 2025 Reduced 2.91%
TSHA Taysha Gene Therapies, Inc.	$125M	$760,000 0.0% of portfolio	547,128	Q1 2025 Added 15.37%
CCCC C4 Therapeutics, Inc.	$112M	$759,000 0.0% of portfolio	474,843	Q1 2025 Reduced 2.37%
KMPH Kempharm, Inc	$170M	$757,000 0.0% of portfolio	153,331	Q1 2025 Added 2.56%
TNGX Tango Therapeutics, Inc.	$594M	$750,000 0.0% of portfolio	548,014	Q1 2025 Added 6.74%
KOD Kodiak Sciences Inc.	$429M	$740,000 0.0% of portfolio	263,370	Q1 2025 Reduced 2.33%
PROK Prokidney Corp Ord Shs Cl A(Cy	$188M	$726,000 0.0% of portfolio	825,647	Q1 2025 Added 8.67%
SGMO Sangamo Therapeutics, Inc	$93.9M	$724,000 0.0% of portfolio	1,097,834	Q1 2025 Reduced 3.64%
CDXS Codexis, Inc.	$212M	$673,000 0.0% of portfolio	250,250	Q1 2025 Added 4.39%
MGNX Macrogenics Inc	$109M	$667,000 0.0% of portfolio	525,535	Q1 2025 Reduced 0.31%
CRBU Caribou Biosciences, Inc.	$144M	$661,000 0.0% of portfolio	727,222	Q1 2025 Reduced 2.48%
ADGI Adagio Therapeutics, Inc.	$505M	$617,000 0.0% of portfolio	186,680	Q4 2024 Reduced 11.42%
THRD Third Harmonic Bio, Inc.	$219M	$614,000 0.0% of portfolio	177,165	Q1 2025 Added 2.29%
OCGN Ocugen, Inc.	$243M	$610,000 0.0% of portfolio	860,244	Q4 2024 Added 12.16%
MCRB Seres Therapeutics, Inc.	$1.66B	$583,000 0.0% of portfolio	834,107	Q1 2025 Reduced 3.66%
TERN Terns Pharmaceuticals, Inc.	$220M	$569,000 0.0% of portfolio	206,450	Q4 2024 Added 33.44%
CMPX Compass Therapeutics, Inc.	$320M	$565,000 0.0% of portfolio	297,880	Q1 2025 Added 4.08%
FATE Fate Therapeutics Inc	$121M	$556,000 0.0% of portfolio	703,825	Q1 2025 Reduced 8.63%
SAVA Cassava Sciences Inc	$101M	$541,000 0.0% of portfolio	361,253	Q1 2025 Added 12.98%
CRDF Cardiff Oncology, Inc.	$168M	$533,000 0.0% of portfolio	169,974	Q1 2025 Added 67.19%
LXRX Lexicon Pharmaceuticals, Inc.	$213M	$529,000 0.0% of portfolio	1,150,771	Q1 2025 Reduced 3.39%
PLRX Pliant Therapeutics, Inc.	$77.4M	$525,000 0.0% of portfolio	389,349	Q1 2025 Reduced 15.25%
VTYX Ventyx Biosciences, Inc.	$181M	$515,000 0.0% of portfolio	448,345	Q1 2025 Reduced 8.26%
CADL Candel Therapeutics, Inc.	$196M	$473,000 0.0% of portfolio	83,880	Q1 2025 Added 60.72%
VYGR Voyager Therapeutics, Inc.	$128M	$464,000 0.0% of portfolio	137,571	Q4 2024 Added 0.07%
XOMA Xoma Corp	$296M	$461,000 0.0% of portfolio	23,158	Q1 2025 Added 0.19%
QSI Quantum Si Inc	$236M	$440,000 0.0% of portfolio	367,444	Q1 2025 Added 19.29%
BMEA Biomea Fusion, Inc.	$53M	$386,000 0.0% of portfolio	181,380	Q1 2025 Reduced 9.48%
FENC Fennec Pharmaceuticals Inc.	$229M	$372,000 0.0% of portfolio	61,146	Q4 2024 Added 10.27%
PBYI Puma Biotechnology, Inc.	$149M	$350,000 0.0% of portfolio	118,254	Q1 2025 Added 0.5%
INMB Inmune Bio, Inc.	$48.1M	$322,000 0.0% of portfolio	41,320	Q1 2025 Added 19.19%
RGLS Regulus Therapeutics Inc.	$119M	$313,000 0.0% of portfolio	178,879	Q2 2024 New
APLT Applied Therapeutics Inc.	$22.1M	$309,000 0.0% of portfolio	632,529	Q1 2025 Reduced 9.75%
CMRX Chimerix Inc	$748M	$301,000 0.0% of portfolio	35,437	Q1 2025 Reduced 32.7%
ELYM Eliem Therapeutics, Inc.	$109M	$288,000 0.0% of portfolio	70,093	Q3 2024 Added 309.23%
ATOS Atossa Therapeutics, Inc.	$109M	$283,000 0.0% of portfolio	422,582	Q1 2025 Added 40.09%
SCPH Sc Pharmaceuticals Inc.	$155M	$278,000 0.0% of portfolio	105,935	Q1 2025 Added 3.0%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.